CSIMarket
 
Nuvation Bio Inc   (NUVB)
 

company, contraction in the company conduct during the most recent fiscal period

delivered third quarter of 2022 operating shortfall of $-29.338 millions


Published Nov 06 2022
CSIMarket Team / CSIMarket.com


Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons While the July to September 30 2022 reporting cycle continues, many companies have declared the respective numbers. Among them, have been various companies in the Major Pharmaceutical Preparations sector. And now, NUVB announced operating shortfall of $-29.338 millions, for the third quarter of 2022 earnings season.

The brilliant policy to contextualize the most recent fiscal period result, at the current situation of the firm. Now, it's simple to compare the operating shortfall of the third quarter of 2021, as it came in $-22.791 millions.


The CEO is pursuing numerous corporate policies, in attempt to secure new service. Over the same period the net loss, which the company has dealt with amid the expanding span, has expanded to $-27.203 millions, from $-21.979 millions, relative to the Q3 of 2021.


Nuvation Bio Inc is expected to report next financial recent numbers on May 08, 2023.



Nuvation Bio Inc's Price to sales ratio PS

Nuvation Bio Inc's Dividend Comparisons



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com